Sangamo Therapeutics Net Worth
Sangamo Therapeutics Net Worth Breakdown | SGMO |
Sangamo Therapeutics Net Worth Analysis
Sangamo Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sangamo Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sangamo Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sangamo Therapeutics' net worth analysis. One common approach is to calculate Sangamo Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sangamo Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sangamo Therapeutics' net worth. This approach calculates the present value of Sangamo Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sangamo Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sangamo Therapeutics' net worth. This involves comparing Sangamo Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sangamo Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Sangamo Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sangamo Therapeutics' net worth research are outlined below:
| Sangamo Therapeutics is way too risky over 90 days horizon | |
| Sangamo Therapeutics appears to be risky and price may revert if volatility continues | |
| Sangamo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 176.23 M. Net Loss for the year was (257.83 M) with loss before overhead, payroll, taxes, and interest of (138.6 M). | |
| Sangamo Therapeutics currently holds about 315.72 M in cash with (224.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02. | |
| Sangamo Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Sangamo Therapeutics Upgraded to Buy at StockNews.com |
Sangamo Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sangamo Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sangamo Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Sangamo Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sangamo Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sangamo Therapeutics backward and forwards among themselves. Sangamo Therapeutics' institutional investor refers to the entity that pools money to purchase Sangamo Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-09-30 | 664.6 K | Jane Street Group Llc | 2024-06-30 | 600.6 K | Fmr Inc | 2024-09-30 | 544 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 493.7 K | Macquarie Group Ltd | 2024-09-30 | 400 K | Susquehanna International Group, Llp | 2024-09-30 | 392.8 K | Group One Trading, Lp | 2024-09-30 | 382.8 K | Northern Trust Corp | 2024-09-30 | 381.2 K | Tudor Investment Corp Et Al | 2024-09-30 | 363.5 K | Wasatch Advisors Lp | 2024-09-30 | 19.4 M | Vanguard Group Inc | 2024-09-30 | 9.6 M |
Follow Sangamo Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 563.24 M.Market Cap |
|
Project Sangamo Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.56) | (1.48) | |
| Return On Capital Employed | (2.33) | (2.21) | |
| Return On Assets | (1.56) | (1.48) | |
| Return On Equity | (3.11) | (2.96) |
When accessing Sangamo Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sangamo Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sangamo Therapeutics' profitability and make more informed investment decisions.
Evaluate Sangamo Therapeutics' management efficiency
Sangamo Therapeutics has return on total asset (ROA) of (0.5829) % which means that it has lost $0.5829 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9405) %, meaning that it created substantial loss on money invested by shareholders. Sangamo Therapeutics' management efficiency ratios could be used to measure how well Sangamo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of December 2024, Return On Tangible Assets is likely to grow to -1.48. In addition to that, Return On Capital Employed is likely to grow to -2.21. At this time, Sangamo Therapeutics' Total Assets are very stable compared to the past year. As of the 3rd of December 2024, Non Currrent Assets Other is likely to grow to about 19 M, while Other Assets are likely to drop 0.95.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.48 | 0.45 | |
| Tangible Book Value Per Share | 0.48 | 0.45 | |
| Enterprise Value Over EBITDA | (1.00) | (1.05) | |
| Price Book Value Ratio | 1.14 | 1.09 | |
| Enterprise Value Multiple | (1.00) | (1.05) | |
| Price Fair Value | 1.14 | 1.09 | |
| Enterprise Value | 78.9 M | 75 M |
Sangamo Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 8.7982 | Revenue 12.3 M | Quarterly Revenue Growth (0.95) | Revenue Per Share 0.066 | Return On Equity (1.94) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sangamo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sangamo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sangamo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sangamo Therapeutics Corporate Filings
F4 | 26th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 28th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Sangamo Therapeutics Earnings per Share Projection vs Actual
Sangamo Therapeutics Corporate Management
| Phillip Ramsey | Head Operations | Profile | |
| David Ojala | Scientist Research | Profile | |
| Mark McClung | Ex COO | Profile | |
| Stephanie CLP | Head Management | Profile | |
| Whitney Jones | VP Officer | Profile | |
| Andrew Ramelmeier | Ex Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.95) | Return On Assets (0.58) | Return On Equity (1.94) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.